Description
An adenosine A1 receptor antagonist (Ki = 1 nM); selective for adenosine A1 over A2A, A2B, and A3 receptors (Kis = 398, 3,981, and 200 nM, respectively); decreases adenosine A1 receptor-mediated adenosine-induced bradycardia in rats (ED50 = 0.49 mg/kg) but reduces A2 receptor-mediated adenosine-induced hypotension by only 44.6% at an intravenous dose of 5 mg/kg; prevents increases in heart levels of collagen I and III in nephrectomized rats at 10 mg/kg per day; reduces relative plaque counts in a Zika virus plaque-forming assay in A549 cells (IC50 = 58.6 nM) in an adenosine A1 receptor-independent manner
Formal name: trans-4-[(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-cyclohexanol
Synonyms: SLV 320
Molecular weight: 308.4
CAS: 251945-92-3
Purity: ≥98%
Formulation: A solid
Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypotension||Research Area|Cardiovascular System|Heart|Arrhythmia||Research Area|Cardiovascular System|Kidney & Renal Disease||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|Zika